Background-Activation of ε protein kinase C (εPKC) protects hearts from ischemic injury. However, some of the mechanism(s) of εPKC mediated cardioprotection are still unclear. Identification of εPKC targets may aid to elucidate εPKC-mediated cardioprotective mechanisms. Previous studies, using a combination of εPKC transgenic mice and difference in gel electrophoresis (DIGE), identified a number of proteins involved in glucose metabolism, whose expression was modified by εPKC. These studies, were accompanied by metabolomic analysis, and suggested that increased glucose oxidation may be responsible for the cardioprotective effect of εPKC. However, whether these εPKC-mediated alterations were due to differences in protein expression or phosphorylation was not determined.
Introduction
We previously developed and used an εPKC isoenzyme-selective activator peptide and found that εPKC activation reduces cardiac cell death induced by ischemia 1, 2 . To provide insight into εPKC-mediated cytoprotective mechanisms, we used a proteomic approach combining antibodies that specifically recognize proteins phosphorylated at the PKC consensus phosphorylation site and an εPKC activator peptide 3 . This approach led to the identification of mitochondrial aldehyde dehydrogenase 2 (ALDH2) as an εPKC substrate, whose phosphorylation and activation is necessary and sufficient to induce cardioprotection during an ischemic injury 3 . We also demonstrated that the cytoprotective mechanism of εPKC is mediated, at least in part, by ALDH2-mediated detoxification of reactive aldehydes, such as 4-hydroxy-2-nonenal (4-HNE), that accumulate in the heart during ischemia [3] [4] [5] . Studies by others, using transgenic and dominant negative εPKC mice, identified other εPKC signaling complexes, composed of proteins involved in glucose and lipid metabolism, and proteins related to transcription/ translation, suggesting that εPKC-mediated cytoprotection involves regulation of other cellular processes [6] [7] [8] . A study using difference in gel eletrophoresis (DIGE) comparing hearts of mice overexpressing catalytically active and dominant negative εPKC identified alterations in the levels of proteins involved in glucose metabolism. Metabolomic studies confirmed that during ischemia/ reperfusion glucose is metabolized faster in animals expressing constitutively active εPKC 9 . However, these studies did not clarify whether the differences in the identified proteins were due to differential expression or phosphorylation levels. Overexpression of εPKC lead to its mislocalization 10 and a compensatory effect observed by δPKC overexpression 9 . Therefore, some of the targets identified in this study could possibly have been phosphorylated by overexpressed δPKC or mis-localized εPKC. Nevertheless, these studies suggested that the cardioprotective mechanism of εPKC is also due to the regulation of glucose and lipid metabolism.
In the present study we used an adult heart Langendorff coronary perfusion system, and treated isolated hearts with an εPKC specific activator peptide (ψεRACK) prior to ischemia, to determine phosphorylation events, following selective activation of εPKC. Proteins whose phosphorylation increased in the presence of ψεRACK were detected in 2D Gels with a phospho-specific dye. Mass spectrometry of the phosphorylated proteins demonstrated that most of the proteins identified in total heart lysates that were differentially phosphorylated upon εPKC activation were mitochondrial proteins. Isolation of mitochondria from ψεRACK treated and control hearts confirmed that εPKC activation led to an increase inphosphorylation levels of proteins involved in, the electron transport chain as well as lipid metabolism.
Materials and Methods

Ex vivo rat heart model of cardiac ischemia
Animal protocols were approved by the Stanford University Institutional Animal Care and Use Committee. Rat hearts (Wistar, 250-300g), each group consisting of three rats, were perfused via the aorta at a constant flow rate of 10 ml/min with oxygenated Krebs-Henseleit buffer (120 mM NaCl, 5.8 mM KCl, 25 mM NaHCO3, 1.2 mM NaHCO3, 1.2 mM MgSO4, 1.2 mM CaCl2, and 10 mM dextrose, pH 7.4) at 37°C. After a 20 min. equilibration period, hearts were subjected to 35 min global, no-flow ischemia. The εPKC-selective agonist ψεRACK peptide [ HDAPIGYD 11 fused to the cell permeable Tat protein transduction domain peptide, amino acids 47-57 12 (1mM) was perfused for 10 min immediately prior to ischemia onset.
Preparation of heart lysates and sub-cellular fractionation
At the end of ischemia, hearts were removed from the cannnula and immediately homogenized on ice to obtain total and mitochondrial fractions. To obtain the total lysate fraction, heart ventricles were homogenized in BufferA [7M urea, 2M tiourea, 4% CHAPS, 5mM magnesium acetate, 17μg/mL PMSF and phosphatase inhibitor cocktail diluted 1:300 (Sigma # P8340 and Sigma # P5726)]. To obtain the mitochondrial fraction, heart ventricles were homogenized in ice-cold mannitol-sucrose (MS) buffer [210 mM mannitol, 70 mM sucrose, 5 mM MOPS and 1mM EDTA containing Protease) and phosphatase Inhibitors as above]. The homogenate was centrifuged at 700g for 10 minutes (to pellet the cytoskeletal fraction), the resultant supernatant was filtered through gauze, and centrifuged at 10,000g for 10 minutes (to pellet the mitochondrial fraction). The mitochondrial pellet was washed 3x in MS buffer before the pellet was resuspended in DIGE buffer.
Two-Dimensional Gel Electrophoresis
Protein samples (300μg for analytic gels and 500 μg for preparative gels of total heart lysate and 250 μg for analytic/ preparative gels of mitochondrial fraction) were applied onto 3-10 linear immobilized pH gradient strips (13cm, GE, Healthcare, Life Science). Strips were rehydrated for 16 hours at room temperature. Isoelectric focusing (IEF) was performed on an IPGphor III apparatus (GE Healthcare Life Science) at 17 KVh. For the second dimension strips were incubated at room temperature, for 20 min in equilibration buffer [6 M urea, 2% (w/v) SDS, 50 mM Tris-HCl pH 6.8, 30% (v/v) glycerol, 0.001% (w/v) bromophenol blue] with 2% (w/v) DTT, followed by incubation with 4% (w/v) iodoacetamide in equilibrium buffer, for 20 min. The second dimension was separated using vertical SDS-PAGE. Experiments were performed in triplicates. Phospho-proteins were detected by staining with Pro-Q Diamond (Invitrogen) per manufacturer's instructions. Gels were scanned using a Typhoon TRI scanner (Healthcare Life Science), stained with Coomassie Brilliant Blue G250 (CBB) 13 and scanned using a UTA-1100 scanner and Labscan v 5.0 software (GE Healthcare Life Science).
Image analysis was performed using Image Master Software v.5.01 (GE Healthcare Life Science). For each pair of samples analyzed, individual spot volumes of replicate gels were determined in Pro-Q Diamond stained gels (phospho-proteins), followed by normalization (individual spot volume/ volume of all spots × 100). Spots (of treated samples) that appeared or showed a change in spot volume of least 1.5 fold as compared to samples of hearts submitted to ischemia alone were excised from CBB-stained preparative gels and identified by mass spectrometry. Differences between experimental groups were evaluated by the Mann-Whitney t-test for proteomic analysis. A * p value < 0.05 was considered statistically significant.
"In-gel" protein digestion and MALDI-TOF/TOF MS
Digestion of selected spots was performed as previously described 14 . Matrix-Assisted Laser Desorption ionization Time-of-Flight/Time-of-Flight Mass Spectrometry) as analysis executed aspreviously described 15 . MASCOT MS/MS Ion Search (www.matrixscience.com) software was used to blast sequences against the SwissProt and NCBInr databanks. Combined MS-MS/MS searches were conducted with parent ion mass tolerance at 50 ppm, MS/MS mass tolerance of 0.2 Da, carbamidomethylation of cysteine (fixed modification) and methionine oxidation (variable modification). According to MASCOT probability analysis only hits with significant P < 0.05 were accepted Spots from total lysates were identified at the Mass Spectrometry Facility at Stanford University (massspec.stanford.edu).
Results
Identification of phosphoproteins
Hearts were exposed to global, no-flow ischemia (35 min) in the presence or absence of ψεRACK (1μM) applied for normoxia 10 min prior to an ischemic onset, with no wash-out, as previously described 16 . Both groups had a 20 min equilibration period, after which hearts were subjected to 30 min global, no-flow ischemia. To one of the groups the εPKC-selective agonist peptide, ψεRACK, was perfused for 10 min (1μM), immediately prior to ischemia onset and kept throughout ischemia. Total lysate of 3 hearts, from 3 independent experiments, were prepared, and run individually on 2D gels. Considering phosphorylated spots that had at least a 1.5X increase, we compared phosphorylated spots from hearts of animals subjected to, ischemia and ψεRACK + ischemia. The phosphorylation of 20 spots increased only in ischemic hearts treated with ψεRACK. Of these, 18 spots were identified by mass spectrometry (Figure 1, 2 and Table 1 ).
Since the majority of the proteins (~70%) identified were mitochondrial proteins and since a number of previous studies demonstrated that εPKC can interact with and phosphorylate mitochondrial proteins 8, [17] [18] [19] [20] we set out to analyze the εPKC phosphoproteome in isolated mitochondria.
Identification of phosphoproteins in mitochondrial fractions
Mitochondria from, ischemia and ψεRACK+ ischemia treated hearts were isolated as described in materials and methods. In a previous study we verified the purity of our mitochondrial preparation by electron microscopy and Western blot analysis of specific mitochondrial proteins 20 . Mitochondrial proteins were separated by 2-D gel electrophoresis and phosphoproteins stained with Pro-Q Diamond. Of the 183 spots that appeared or were increased in gels of mitochondria from hearts of animals treated with ψεRACK + ischemia, 62 spots were visible by Coomassie Brilliant Blue and 56 spots corresponding to 38 different proteins were identified by in-gel excision followed by mass spectrometry ( Figures  3, 4 and Table 2 ). Twenty seven proteins were mitochondrial proteins. Nine proteins were mitochondrial inner membrane proteins and one outer membrane protein. Proteins involved in fatty acid oxidation, electron transport chain (complexes I-IV), heat shock proteins as well as structural proteins were also identified. Interestingly, protein disulfide-isomerase A3 precursor, oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide), tubulin alpha 1A, mitochondrial aconitase, creatine kinase, mitochondrial 2, acyl-Coenzyme A dehydrogenase very long chain, 3-oxoacid CoA transferase 1, carnitine palmitoyltransferase II, electron transfer flavoprotein-ubiquinone oxidoreductase, succinate dehydrogenase complex, subunit A, flavoprotein (Fp), glyceraldehyde 3-phosphate-dehydrogenase, desmin, ubiquinolcytochrome c reductase core protein I and Coq9 protein had a change in more than one phospho-spot indicative of multiple phosphorylation sites.
Recently we showed that translocation of εPKC to the mitochondria is mediated by HSP90, therefore the identified substrates can be direct targets of εPKC 20 . Using scansite (http:// scansite.mit.edu/) we predicted PKC phosphorylation sites of the mitochondrial proteins whose phosphorylation increased upon treatment with ψεRACK. All identified mitochondrial proteins had putative PKC phosphorylation some which matched phosphorylation sites deposited in http://www.phosphosite.org/ (Table 4) .
Discussion
Several lines of evidence suggest that selective εPKC activation reduces cardiac damage due to ischemic injury. Activation of εPKC reduces infarct size and improves functional recovery of the heart 1-3 whereas εPKC inhibition or knockout negates the infarct-sparing effect of ischemic preconditioning 1, 3, 9, 21, 22 . A number of mechanisms have been proposed for εPKC mediated cardioprotection, including regulation of sarcolemmal and/or mitoK ATP channels 17, 23 , regulation of gap-junction permeance through phosphorylation of connexin 43 24 , modulation of proteasomal activity 16 or regulation of mitochondrial permeability transition pore (MPTP) opening through direct phosphorylation of MPTP components 8 . We recently identified mitochondrial ALDH2 as a direct εPKC substrate whose phosphorylation and activation is essential for εPKC-mediated cardioprotection 3 . The cytoprotective mechanism of ALDH2 activation by εPKC is due to the increased metabolism of reactive aldehydes, such as 4-Hydroxy-2-nonenal (4-HNE), which are produced as a by-product of ROS-induced lipid peroxidation, and accumulate, in the ischemic/ reperfused heart 25 . In the present study, we used the Pro-Q Diamond phosphospecific staining method to label proteins whose phosphorylation increased by ψεRACK during ischemia. The majority (~70%) of the εPKC phosphoproteins identified in total heart homogenates treated with ψεRACK during ischemia were mitochondrial proteins. The observation that εPKC activation and cytoprotection results in phosphorylation of mitochondrial proteins and is consistent with other studies reporting that εPKC-mediated cardioprotection is mediated by phosphorylation of mitochondrial proteins 1, 3, 9, 17, 18, 22 .
To provide a more extensive analysis of the εPKC mitochondrial phosphoproteome, we repeated the Pro-Q Diamond analysis on the cardiac mitochondrial-enriched subfraction. In the presence of ψεRACK we saw the appearance of 182 phosphorylated spots, suggesting that εPKC activation results in phosphorylation of a number of mitochondrial proteins. We identified novel mitochondrial εPKC phosphoproteins involved in lipid oxidation, glycolysis, electron transport chain (including proteins from complexes I-IV), ketone body metabolism, and heat shock proteins.
We found an increase in the phosphorylation of inner-mitochondrial protein components of the respiratory chain, (complexes I, II and III); NADH dehydrogenase (ubiquinone) Fe-S protein, electron transfer flavoprotein-ubiquinone oxidoreductase, succinate dehydrogenase complex, subunit A, flavoprotein (Fp) and ubiquinol-cytochrome c reductase core protein I. Our results are in agreement with a number of biochemical and functional analyses which found εPKC to interact with, and phosphorylate inner-mitochondrial proteins involved in mitochondrial respiration [7] [8] [9] 26 . Further, the presence of εPKC in a highly purified inner mitochondrial membrane preparation has already been previously demonstrated 23 . An increase in the activity of the electron transport chain and activation of cytochrome c oxidase subunit IV (COX) by direct εPKC phosphorylation has also been previously demonstrated 27 . COX activation was suggested to be one of the cardioprotective mechanisms of εPKC, possibly due to increased electron flux through the electron transport chain, resulting in enhanced ATP generation and reduced ROS generation 22, 27, 28 . An εPKC-mediated increase in cytochrome c oxidase activity was also shown to protect lens from ischemic damage 29 . Selective activation of εPKC with ψεRACK increased the phosphorylation and activity of complexes I, III and IV in synaptic mitochondria, indicating that other components of the electron transport chain are also regulated by εPKC phosphorylation 30 , and εPKC activation led to a decrease in mitochondrial ROS generation of neuronal mitochondria 30 . In agreement with a role for εPKC in mitochondrial respiration, hearts of constitutively active εPKC transgenic mice demonstrate preserved coupling of oxidative phosphorylation, maintained mitochondrial membrane potential and decreased cytochrome c release induced by ischemic reperfusion 31 . The εPKC transgenic mice used have a mutation of Ala 159 to Glu in the εPKC resulting in constitutively active εPKC and increased resistance to cardiac ischemic reperfusion 8 . Interestingly, in constitutively active εPKC transgenic mice, mitochondrial PKC expression is preferentially increased over cytosolic expression, suggesting that the active form of PKC results in its mitochondrial translocation 8 . Taken together, these data suggest that phosphorylation of intra-mitochondrial targets is crucial for εPKC-mediated cytoprotection. In the present study we identify other components of the respiratory chain and inner mitochondrial phosphorylated proteins. However, whether there is a direct physical association between εPKC and each of the inner mitochondrial εPKC phosphoproteins identified here, and whether these are direct or indirect εPKC substrates remains to be determined. Nevertheless future studies can, be directed by the results obtained here.
We did not detect ALDH2, however this may be due to the fact that different methods of detecting protein phosphorylation have different sensitivities. Some of the εPKC targets identified can be indirect targets whose phosphorylation may be activated upon ALDH2 activation.
Using difference in gel eletrophoresis (DIGE) of cardiac mitochondria from transgenic mice expressing constitutively active or dominant negative εPKC it was found that the majority of spots unique to constitutively active εPKC corresponded to proteins involved in glucose metabolism 9 . These studies were combined with metabolomic studies which detected an increase in glucose metabolites in hearts expressing constitutively active εPKC subjected to ischemia/ reperfusion 9 . The authors proposed that activating glycolytic pathways during ischemia is a novel mechanism for the cardioprotective role of εPKC. In the present study we used a phospho-specific dye and ψεRACK to investigate direct protein phosphorylation events mediated by εPKC. Despite the different methods and methodology used to activate εPKC, (constitutively active transgenic vs. dynamic activation) we identified many of the same proteins, previously described in the DIGE study, including; isocitrate dehydrogenase, oxoglutarate (alpha-ketoglutarate) dehydrogenase, pyruvate dehydrogenase, succinate dehydrogenase. [ 6, 7, 9 and Table 4 ]. We also identified additional εPKC substrates involved in glycolysis, and Krebs cycle such as: aldolase A, ATP-specific succinyl-CoA synthase beta subunit, dihydrolipoamide dehydrogenase (E3), mitochondrial aconitase and aconitase 2, confirming that εPKC activation leads to phosphorylation of proteins involved in glycolysis and the Krebs cycle. Our identification of aconitase as an εPKC target suggests that regulation of the TCA cycle is mediated by εPKC. Aconitase has been previously identified as a PKCβII substrate in diabetic rats, however, aconitase phosphorylation by PKCβII impaired TCA cycle since there was an increase in reverse activity of aconitase (isocitrate to aconitase) 32 . While we identified some proteins identified previously, others were not detected in the present study, such as proteins involved in the Malate/Aspartate shuttle. This could be explained by the different methodology or the sensitivity of the methods (DIGE vs ProQ Diamond) and that we only identified the more abundant phosphorylated proteins. Alternatively, some of the proteins previously detected could have their expression and not phosphorylation status altered 9 . In a study identifying εPKC complexes it has been suggested that εPKC may also play a role in regulating transcription and translation processes 6 . Accordingly, the phosphorylation of Coq9, a key regulator of coenzyme Q synthesis 33 , was also regulated by εPKC in the present study. Further studies should be performed to determine the specific regulation of glycolytic pathways by εPKC phosphorylation and whether different isoenzymes can phosphorylate different sites.
εPKC could also have a direct or indirect role in mitochondrial protein assembly, folding, and import since we identified three mitochondrial heat shock proteins that play a role in the import and folding of proteins inside the mitochondria, and sorting and assembly machinery component 50 (SAM50), homolog of a protein involved in the assembly of outer mitochondrial membrane proteins 34 .
Cardioprotective signals from G protein coupled receptors (GPCRs), activated for example by bradykinin, propagating from the plasma membrane to the mitochondria through signalosomes, vesicular multimolecular complexes derived from caveoli have been previously proposed 35 . In fact εPKC was found in signalosomes and inhibition of εPKC by εV1-2 blocks signalosome stimulation of mitoK ATP 35 . We found two proteins that are found in caveoli, Annexin A2 and PTRF also known as Cavin 36 , these proteins could be part of the signalosome probably co-purified with our mitochondrial fraction. PTRF phosphorylation has been shown to be important in caveoli formation 36 .
Conclusions
A number of mechanisms have been proposed for εPKC-mediated cardioprotection by preconditioning. In the present study we identified several εPKC phosphoproteins which may be responsible for the cardioprotective effect of εPKC. The εPKC targets identified are in line with many of the previously proposed mechanisms for εPKC mediated cardioprotection. We identified components of the signalosome contributing to the idea that εPKC-mediated cardioprotection involves transduction of GPCR signaling to the mitochondria 35 . We also found components of lipid and carbohydrate oxidation pathways consistent with the idea that lipid and carbohydrate metabolism is modulated by εPKC 9 . Activation of the respiratory chain and increase in oxygen consumption have also been proposed to be protective mechanisms of εPKC during preconditioning, to this end we identified components of Krebs cycle, and respiratory chain, whose phosphorylation was modulated by εPKC 27, 29, 30 . The exact mechanisms by which εPKC phosphorylation leads to these different cardioprotective pathways still needs to be elucidated. The data obtained in the present study can therefore direct further studies to characterize the specific role of individual mitochondrial protein phosphorylation in εPKC-mediated cardioprotection. Taken together, our data suggest that εPKC-mediated phosphorylation events in the mitochondria are important for the maintenance of metabolic activity and cardioprotection during ischemic injury. 23 Detection of direct and indirect εPKC substrates in total rat heart lysates. Representative 2DE gels (n= 3 hearts of individual animals) of lysates from control hearts (A and D), hearts subjected to, ischemia alone (B and E) and Ischemia + ψεRACK (C and F) as indicated. Coommassie blue G250 stained gels (A-C) and gels stained with phospho-specific dye Pro-Q Diamond (D-F). Spots used to align gels are labeled (A and D). Coomassie blue G250 stained gel of total heart lysate treated with ψεRACK+ ischemia indicating the spots identified by mass spectrometry whose phosphorylation significantly increased in hearts from rats treated with ψεRACK + ischemia as compared to hearts subjected to ischemia alone. For the annotation of the proteins identified see Table 1 . Detection of direct and indirect εPKC substrates in isolated rat heart mitochondria. Representative 2DE gels (n=3 of mitochondria isolated from individual animals) of lysates from control hearts (A and D) and hearts subjected to, Ischemia (B and E) and ψεRACK+ ischemia (C and F) as indicated. Coommassie blue G250 stained gels (A-C) and gels stained with phospho-specific dye Pro-Q Diamond (D-F). Spots used to align gels are labeled (A and D). Detection of direct and indirect εPKC substrates in isolated rat heart mitochondria. Representative 2DE gels (n=3 of mitochondria isolated from individual animals) of lysates from hearts subjected to, Ischemia and ψεRACK+ ischemia as indicated in figure 1 . Coommassie blue G250 stained gels upper panels and gels stained with phospho-specific dye Pro-Q Diamond, lower panel Table 1 Proteins identified by mass spectrometry whose phosphorylation increased in total heart lysates of hearts subjected to ψεRACK+ ischemia relative to ischemia alone. Identified proteins indicated in figure 2 Table 2 Proteins identified by mass spectrometry whose phosphorylation increased in mitochondria isolated from hearts subjected to ψεRACK+ ischemia relative to ischemia alone. Identified proteins indicated in Figure 6 are shown together with Uniprot accession number, number of peptides identified and, Mascot score, theoretical and experimental molecular weight (M.W.) and 26 isoeletric point. %volume of control (average of three experiments). * P<0.05, as determined by Whitney t-test. 
